Abstract:e13095 Background: Immune checkpoint inhibitors (ICIs) generate an enduring clinical remission in metastatic cancers. However, the efficacy of ICIs monotherapy for triple negative breast cancer (TNBC) is limited. Strategies are urgently needed to enhance anticancer immune responses in TNBC to prolong survival of patients. Methods: BALB/c mice subcutaneous tumor experiments were done to evaluate the efficacy of doxorubicin combined with PD-1 inhibitor, compared with other chemotherapy including cisplatin and paclitaxel. RNA-seq and single-sample gene set enrichment analysis (ssGSEA) were done with our collected mice tumor tissue to observe changes of tumor immune environment in TNBC after chemotherapy combined with immunotherapy. Then, we performed coculture, Transwell assay and FACs in TNBC cell lines, including MDA-MB-231, BT549 and 4T1, and primary CD8+T cells, to assess effects of doxorubicin on CD8+T cell migration in vitro. Gene Ontology (GO) and Kyoto Encyclopedia of Genes, Genomes (KEGG) analysis were enriched from RNA-seq data to seek for a pathway. We analyzed the difference of CD8+T cell infiltration related gene expression, including CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, CXCL11. Western blot, qPCR and ELISA were utilized to explore possible mechanism in stronger migration of CD8+T cells by doxorubicin. Rescue assays were used to confirm the involved mechanisms. Results: Subcutaneous tumor experiment showed that doxorubicin could enhance the efficacy of immune checkpoint inhibitors (p＜0.05),andthe immune microenvironment in TNBC transferred from "anti-inflammatory" to "proinflammatory" status after doxorubicin combined with immunotherapy, compared with other chemotherapy drugs combined with immunotherapy. Higher CD8+T cells infiltration occurred in TNBC treated with doxorubicin in vivo (p＜0.05). The CD8+T cells migration assay demonstrated a higher CD8+T cell migration with doxorubicin in vitro (p＜0.05). KEGG analysis revealed that the chemokine-related pathway was significantly activated after doxorubicin treatment, in which CXCL10 chemokine was most likely to be responsible for CD8+T cell infiltration based on its expression and secretion (both p<0.01). Further experiments demonstrated that the expression of the whole STAT1-IRF1-CXCL10 axis was up-regulated in TNBC mice treated with doxorubicin (p＜0.01), and the STAT1-IRF1-CXCL10 axis was also activated in doxorubicin-treated TNBC cell lines (p＜0.0001). Conclusions: This research demonstrated that doxorubicin can enhance efficacy of immune checkpoint inhibitors through increasing infiltration of CD8+T cells in triple-negative breast cancer via activating STAT1-IRF1-CXCL10 axis. These results provide rationales of doxorubicin combined with PD-1 inhibitor for extending survival of TNBC patients.

Enhancement of Death Receptor 4 Mediated Apoptosis and Cytotoxicity in Renal Cell Carcinoma Cells by Subtoxic Concentrations of Doxorubicin

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (trail) Apoptosis in Vitro but Not in Vivo

Abstract No. 506 Image-guided Radiofrequency Hyperthermia-Enhanced Direct Chemotherapy of Hepatic Tumors: the Underlying Biomolecular Mechanisms

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Experimental Study on Apoptosis of Osteosarcoma Cell Induced by TRAIL Combined with IFN-γ

Supplementary Data from Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis Through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice

Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL

Enhanced Apoptosis: TRAIL‐Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582) (adv. Healthcare Mater. 11/2021)

A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.

Distinctive hippocampal CA2 subfield of the Amazon rodent Proechimys

Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist

Gefitinib Upregulates Death Receptor 5 Expression to Mediate Rmhtrail-Induced Apoptosis in Gefitinib-sensitive NSCLC Cell Line.

Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors in Renal Cell Carcinoma

Therapeutic effects and underlying mechanism of poly (L-glutamic acid)-g-methoxy poly (ethylene glycol)/combretastatin A4/BLZ945 nanoparticles on Renca renal carcinoma

MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer

Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma

Effect of Doxorubicin on Efficacy of Immune Checkpoint Inhibitors Through Increasing Infiltration of CD8-positive T Cells and Activating STAT1-IRF1-CXCL10 Axis